The innovative treatment dry eye is now approved in the UAE. The Emirates Drug Establishment (EDE) has approved MIEBO by Bausch + Lomb. It is used for dry eye disease and helps ease symptoms. This step improves access to modern eye care in the country.
MIEBO contains perfluorohexyloctane. It directly targets tear evaporation, a major cause of dry eye disease. It helps improve tear film stability. It also reduces discomfort and irritation in the eyes.
The approval is based on two clinical studies called GOBI and MOJAVE. More than 1,200 patients took part. The results showed clear improvement in signs and symptoms. The treatment proved effective and safe during trials.
With this approval, the UAE becomes the third country in the world to allow this medicine. It shows the country’s focus on advanced healthcare and fast access to new treatments. The innovative treatment dry eye offers hope for patients suffering from long-term eye dryness. Dry eye disease affects millions globally and can reduce quality of life.
This approval also supports the UAE goal to improve healthcare services. The Emirates Drug Establishment continues to review and approve advanced medicines. Bausch + Lomb’s MIEBO adds a new option for patients with chronic dry eye disease. Doctors expect better outcomes with early use of this treatment.
It also reduces dependence on traditional lubricating eye drops. The focus on perfluorohexyloctane-based therapy shows a shift toward targeting root causes. Patients in the UAE will benefit from faster access to global innovations. This move strengthens the country’s pharmaceutical system and patient care standards.
